A trial testing the use of rivaroxaban (Xarelto) after transcatheter aortic valve replacement (TAVR) has been halted following a raised risk of adverse events with the anticoagulant compared to patients receiving clopidogrel and aspirin. In a letter to healthcare professionals rivaroxaban manufacturer Bayer noted that back in August the data safety monitoring board had recommended ...
Rivaroxaban trial after TAVR stopped due to adverse events
By Nicola Garrett
18 Oct 2018